Cansino Biologics Stock Total Debt
| CASBF Stock | USD 3.90 0.00 0.00% |
CanSino Biologics fundamentals help investors to digest information that contributes to CanSino Biologics' financial success or failures. It also enables traders to predict the movement of CanSino Pink Sheet. The fundamental analysis module provides a way to measure CanSino Biologics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to CanSino Biologics pink sheet.
CanSino |
CanSino Biologics Company Total Debt Analysis
CanSino Biologics' Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Current CanSino Biologics Total Debt | 40 M |
Most of CanSino Biologics' fundamental indicators, such as Total Debt, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, CanSino Biologics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
| Competition |
Based on the latest financial disclosure, CanSino Biologics has a Total Debt of 40 M. This is 98.55% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The total debt for all United States stocks is 99.25% higher than that of the company.
CanSino Total Debt Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses CanSino Biologics' direct or indirect competition against its Total Debt to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of CanSino Biologics could also be used in its relative valuation, which is a method of valuing CanSino Biologics by comparing valuation metrics of similar companies.CanSino Biologics is currently under evaluation in total debt category among its peers.
CanSino Fundamentals
| Return On Equity | 0.0111 | |||
| Return On Asset | -0.0207 | |||
| Profit Margin | 0.06 % | |||
| Operating Margin | (0.19) % | |||
| Current Valuation | 3.58 B | |||
| Shares Outstanding | 114.78 M | |||
| Shares Owned By Insiders | 26.70 % | |||
| Shares Owned By Institutions | 38.17 % | |||
| Price To Earning | 19.25 X | |||
| Price To Book | 2.30 X | |||
| Price To Sales | 2.51 X | |||
| Revenue | 4.3 B | |||
| Gross Profit | 3 B | |||
| EBITDA | 2.05 B | |||
| Net Income | 1.91 B | |||
| Cash And Equivalents | 7 B | |||
| Cash Per Share | 28.36 X | |||
| Total Debt | 40 M | |||
| Debt To Equity | 0.26 % | |||
| Current Ratio | 2.99 X | |||
| Book Value Per Share | 29.22 X | |||
| Cash Flow From Operations | 2.05 B | |||
| Earnings Per Share | 0.59 X | |||
| Number Of Employees | 1.95 K | |||
| Beta | 0.61 | |||
| Market Capitalization | 3.15 B | |||
| Total Asset | 11.87 B | |||
| Z Score | 46.8 | |||
| Annual Yield | 0.01 % | |||
| Net Asset | 11.87 B | |||
| Last Dividend Paid | 0.8 |
About CanSino Biologics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze CanSino Biologics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of CanSino Biologics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of CanSino Biologics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in CanSino Pink Sheet
CanSino Biologics financial ratios help investors to determine whether CanSino Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in CanSino with respect to the benefits of owning CanSino Biologics security.